Parker Institute for Cancer Immunotherapy
@parkerici
Our mission is to accelerate the development of breakthrough immune therapies to turn all cancers into curable diseases.
ID: 702942034399780864
http://parkerici.org 25-02-2016 19:43:35
3,3K Tweet
11,11K Followers
574 Following
Debolina Ganguly, PhD (Debolina Ganguly), a 2024 Parker Scholar at Dana-Farber, studies how metastatic stem cells promote systemic tolerance to tumor antigens & suppress responses to immunotherapy, advancing understanding of patient response. Hear more about PICI’s support of her work.
Max Foisey, a 2024 Parker Scholar, is leveraging synthetic biology to enhance CAR T-cell therapies for solid tumors. Hear more about his innovative recent research & work within the Roybal Lab alongside Dr. Kole Roybal, PICI Center Director UC San Francisco below.
The latest Immuno-Oncology Digest is live, featuring news and updates from the PICI Network, including the PICI-sponsored AMADEUS trial, ArsenalBio’s Series C, cutting-edge research publications & more: mailchi.mp/parkerici/the-…
Sean Yamada-Hunter, PhD, was recently named a 2024 Parker Scholar as part of PICI’s Early Career Researcher awards program. The award will contribute to his cutting-edge research in combining CAR T-cell therapy with anti-CD47 therapy at Stanford Medicine. Learn more from Sean below.